---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268072"
form_type: "8-K"
ticker: "RAPP"
cik: "0002012593"
company_name: "Rapport Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:03:09.701994+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rapport: Phase 2a RAP-219 meets endpoints; 77.8% median seizure reduction; Q3 net loss $26.9M

## Summary
- Phase 2a in drug-resistant focal seizures: 77.8% median clinical seizure reduction, 24% seizure freedom, 85.2% with ≥30% LE reduction (all p<0.01).
- End-of-Phase 2 FDA meeting by end 2025; two Phase 3 FOS trials to start Q3 2026.
- Q3 net loss $26.9M (vs $17.5M YoY); R&D $22.3M, G&A $7.7M.
- Cash, equivalents, and ST investments $513.0M; includes $269.4M net from September public offering.
- Bipolar mania Phase 2 enrolling; topline expected H1 2027. DPNP trial on FDA clinical hold; update Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-268072
- form_type: 8-K
- ticker: RAPP
- cik: 0002012593
- company_name: Rapport Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2012593/000119312525268072/0001193125-25-268072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2012593/000119312525268072/rapp-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268072
- JSON: https://secwatch.observer/filing/0001193125-25-268072.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.